Boehringer Ingelheim today announced breakthrough results from a survodutide Phase II trial sub-analysis that demonstrate up to 64.5% of adults with fibrosis stages F2 and F3 (moderate to advanced scarring) achieved an improvement in fibrosis without worsening of metabolic dysfunction-associated steatohepatitis…
Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable. This collaboration will offer people an opportunity to learn about and potentially participate in an important Phase III clinical trial within the familiar and accessible environment of Walgreens…
Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm), the company’s interchangeable biosimilar to Humira® (adalimumab), to treat multiple chronic inflammatory diseases. “With this FDA approval, we are now able…
Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has approved SPEVIGO® (spesolimab-sbzo) injection for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and above weighing ≥40 kg. This approval follows the Chinese…
Evren Özlü, who has been serving as the Head of Animal Health for the India, Middle East, Turkey, and Africa Region (IMETA) at Boehringer Ingelheim, has been appointed as the Head of Human Pharma for the IMETA Region. Evren Özlü,…
With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications, some of them in the late-stage development of the company’s strong innovation pipeline. The main disease areas include cardio-renal-metabolic (CRM) diseases,…
Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s leading experience in the discovery and clinical development of…
Boehringer Ingelheim and IBM announced an agreement that will enable Boehringer to use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics. “We are very excited to collaborate with the research team at IBM,…
Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals (“T3 Pharma”), a clinical stage Swiss biotech company, for an amount of up to 450 million CHF. T3 Pharma has developed a proprietary therapy platform that uses live bacteria to…
Boehringer Ingelheim announced that FDA has granted Orphan Drug Designation to BI 1819479 for the potential treatment of idiopathic pulmonary fibrosis (IPF). BI 1819479 is an investigational compound that may address pulmonary fibrosis—a scarring of the lung tissue that negatively…